Preview

User

Not a user? Register with this site Forgot your password?

Problems of Endocrinology

Advanced search

The influence of sibutramine therapy on the body composition and metabolic characteristics of the patients presenting with exogenous constitutional obesity

Abstract

The treatment of 36 patients suffering exogenous constitutional obesity (ECO) with sibutramine during 12 weeks resulted in the substantial reduction of body weight, waist circumference (WC), hip circumference (HC), and waist-to-hip ratio (WHR). Simultaneously, the total cholesterol level in the blood decreased. The reduction in the body weight had positive effect on carbohydrate metabolism. Medicamental treatment of obesity caused a drop in systolic arterial pressure and a substantial change in the body composition. Specifically, percentage of both total and visceral fat as well as basal metabolism decreased, water retention in the body increased while the muscular mass remained unaltered. It is concluded that the introduction of Sibutramine into the combined treatment of exogenous constitutional obesity effectively promotes the reduction of the body weight, improvement of the body composition and metabolic characteristics.

Keywords


References

1. World Health Organization Obesity and overweight facts (удаленный доступ: http://www.who.int/mediacentre/factsheets/fs311/en/index.html] (accessed July 2005).

2. Бутрова С.А. Сибутрамин (меридиа) в лечении ожирения: опыт применения в России. Клин фарм и тер 2001; 10: 2: 71-74.

3. Rang H.P., Dale M.M., Ritter J.M., Moore P.K. Pharmacology (5th Ed.). Lovington (Edinburg) 2004; 394-403.

4. Cummings D.E., Schwartz M.W. Genetics and pathophysiology of human obesity. Ann Rev Med 2003; 54: 453-471.

5. Харкевич Д.А. Фармакология. М 2004; 350-351, 497-500.

6. Kopelman P.G., Grace C. New thoughts on managing obesity. Gut 2004; 53: 7: 1044-1053.

7. Labib M. acp Best Practice No 168. The investigation and management of obesity. J Clin Pathol 2003; 56: 1: 17-25.

8. Murphy K.G., Bloom S.R. Gut hormones in the control of appetite. Exp Physiol 2004; 89: 5: 507-516.

9. Payer J., Hainer V., Ondrejka P. et al. Sibutramin in obesity treatment (multicenter, open, prospective 12-month-long study) J Vnitr Lek 2004; 50: 11: 825-829.

10. Finer N. Does pharmacologically induced weight loss improve cardiovascular outcome? Impact of anti-obesity agents on cardiovascular risk factors. Eur Heart J 2005; Suppl 7: Suppl L: L32-L38.

11. Hainer V., Kabrnova K., Aldhoon B. et al. Serotonin and norepinephrine reuptake inhibition and eating behavior. Ann NY Acad Sci 2006; 1083: 252-269.

12. Luque C.A., Rey J.A. The discovery and status of sibutramine as an anti-obesity drug. Eur J Pharmacol 2002; 440: 2-3: 119-128.

13. Phelan S., Wadden T.A. Combining behavioral and pharmacological treatments for obesity. Obes Res 2002; 10: 6: 560-574.

14. Kennedy G.C. The role of depot fat in the hypothalamic control of food intake in the rat. Proc R Soc Lond B Biol Sci 1953; 140: 901: 578-596.

15. Bray G.A., Ryan D.H., Gordon D. et al. A double-blind randomized placebo-controlled trial of sibutramine. Obestet Res 1996; 4: 3: 263-270.

16. James W.P, Astrup A., Finer N et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356: 9248: 2119-2125.

17. Philip W., James T., Ian D. et al. Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects. N Engl J Med 2010; 363: 905-917.

18. Bjorntorp P., Holm J., Rosmond R. Hypothalamic arousal, insulin resistance and Type 2 diabetes mellitus. Diabet Med 1999; 16: 5: 373-383.

19. Дедов И.И., Мельниченко Г.А. Ожирение. Руководство для врачей. М 2004; 52-53.

20. Harris R.B., Kasser T.R., Martin R.J. Dynamics of recovery of body composition after overfeeding, food restriction or starvation of mature female rats. J Nutr 1986; 116: 12: 2536-2546.

21. Gibbs J., Young R.C., Smith G.P. Cholecystokinin decreases food intake in rats. J Comp Phys Psychol 1973; 84: 3: 488-495.


Review

For citations:

Vlasova I.I., Ametov A.S. The influence of sibutramine therapy on the body composition and metabolic characteristics of the patients presenting with exogenous constitutional obesity. Problems of Endocrinology. 2012;58(1):34-38.

Views: 2757


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 0375-9660 (Print)
ISSN 2308-1430 (Online)

11, Dm. Ul’yanova str., Moscow, Russian Federation, 117292

Processing of personal data
supported by NEICON (Elpub lab)